Finally, the data on the gene expression profiles of cancer cell lines were integrated in the Genomics of Drug Sensitivity in Cancer (GDSC) database for drug sensitivity to fully explore the potential value of CDKN2A, DLAT, DLST, GLS, and PDHA1 genes as novel therapeutic targets. This evidence concerns the gene CDKN2A and cancer.